Recent treatments of interstitial lung disease with systemic sclerosis

Hidekata Yasuoka

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Systemic sclerosis (SSc) is a disorder characterized by immune dysfunction, microvascular injury, and fibrosis. Organ involvement in patients with SSc is variable; however, pulmonary involvement occurs in up to 90% of patients with SSc. Interstitial lung disease (ILD) is a major cause of mortality and, thus, a major determinant in the prognosis of patients with SSc. This review summarizes current findings about the characteristics of ILD in patients with SSc, selection of patients with SSc-ILD who are candidates for the treatment, and current treatment options.

Original languageEnglish
Pages (from-to)97-110
Number of pages14
JournalClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Publication statusPublished - 2016 Jan 19


  • Interstitial lung disease
  • Pulmonary hypertension
  • Systemic sclerosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Recent treatments of interstitial lung disease with systemic sclerosis'. Together they form a unique fingerprint.

Cite this